ACLX News and Press, Arcellx Inc. From 05/17/22

The following slide deck was published by Arcellx, Inc. in conjunction with this event. For further details see: Arcellx (ACLX) Investor Presentation - Slideshow

Arcellx Appoints Olivia Ware to Board of Directors PR Newswire -- Replaces Lewis T. "Rusty" Williams, M.D., on Board of Directors -- FOSTER CITY, Calif. , May 16, 2022 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagin...

Arcellx press release (NASDAQ:ACLX): Q1 GAAP EPS of -$1.56 misses by $0.46. As of March 31, 2022, Arcellx had cash, cash equivalents, and marketable securities of $210.9 million, which is anticipated to fund its operations into the second half of 2023. For further details see: Arcellx G...

Arcellx Provides Business Updates and Reports First Quarter 2022 Financial Results PR Newswire -- First patient dosed in the Phase 1 clinical trial evaluating ACLX-001 utilizing groundbreaking ARC-SparX technology in relapsed or refractory multiple myeloma (r/r MM) -...

Arcellx Announces Dosing of First Patient in its Phase 1 Clinical Trial Evaluating ACLX-001, the First Therapeutic in the Dosable and Controllable ARC-SparX Platform, for the treatment of Patients with Relapsed or Refractory Multiple Myeloma PR Newswire -- ARC-SparX is a...

Arcellx Announces Publication in Blood Advances of Clinical Results from the Dose Escalation Cohorts of its CART-ddBCMA Phase 1 Study in Patients with Relapsed or Refractory Multiple Myeloma PR Newswire 100% ORR ; 75% CR/sCR; and evidence of durable clinical benefit ...

Arcellx Announces Participation at the BofA Securities 2022 Healthcare Conference PR Newswire FOSTER CITY, Calif. , May 5, 2022 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of ...

Arcellx to Present New Clinical Data from its CART-ddBCMA Phase 1 Trial in Patients with Relapsed or Refractory Multiple Myeloma in an Oral Abstract Session at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting PR Newswire -- Company to host a live webc...

Arcellx (ACLX) shares jumped 12% on Monday following a week of declines. Shares of the biotech group opened at $11.23 and hit a high of $11.97 in early afternoon. The stock recently changed hands at $11.94, up 12%, at approximately 1:15 p.m. Based in Maryland, Arcellx has been developing cell...

Arcellx Presents Pre-Clinical Data for ACLX-002, a Novel CD123-targeted Universal CAR-T Cell Therapy for Relapsed or Refractory Acute Myeloid Leukemia at the American Association for Cancer Research Annual Meeting PR Newswire -- ACLX-002 completely regresses multiple c...